Physician profile
Melissa Rosso
NPI 1720216708
$2,063.12
in general payments reported to CMS, 2019-2025
26 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.07 · 2020: $69.51 · 2021: $192 · 2022: $526 · 2023: $583 · 2024: $237 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $396.88 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $279.51 | 2020-2025 | |
| Amgen INC. | $243.64 | 2019-2023 | Otezla, Repatha |
| Novo Nordisk INC | $212.93 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $156.88 | 2020-2024 | Breztri, Airsupra |
| Lilly USA, LLC | $114.70 | 2023-2025 | Mounjaro, Jardiance |
| Dexcom, INC. | $76.60 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Merck Sharp & Dohme LLC | $54.29 | 2021-2023 | Steglatro, Belsomra |
| Glaxosmithkline, LLC. | $45.78 | 2021-2025 | Shingrix, Bexsero, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.34 | 2023-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.22 | 2022-2023 | Synjardy, Tradjenta |
| Sanofi Pasteur INC. | $44.66 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $42.96 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $42.42 | 2019-2025 | Veozah |
| Abbott Laboratories | $40.90 | 2021-2024 | Freestyle Libre 3 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $40.30 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $25.10 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.99 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.82 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $19.00 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $18.27 | 2021 | |
| Esperion Therapeutics, INC. | $16.31 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.42 | 2021 | |
| Exact Sciences Corporation | $13.81 | 2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $13.31 | 2021 | |
| Radius Health, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Rosso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.